JPRN-UMIN000006113已完成2 期
A Phase II Study of Pemetrexed in chemo-naive Elderly Patients with Lung Adenocarcinoma and An exploratory study on Mechanisms of chemotherapy resistance. - A Phase II Study of Pemetrexed in chemo-naive Elderly Patients with Lung Adenocarcinoma and An exploratory study on Mechanisms of chemotherapy resistance.
Division of Respirology, department of internal medicine, Jikei University Hospital0 个研究点目标入组 32 人开始时间: 2011年8月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Symptomatic brain metastasis 2. Massive pleural effusion 3. Hystory of active double cancer 4. History of uncontrollable diabetes mellitus, active angina pectoris, recent myocardial infaction, and severe complications 5. History of active infection
研究者
相似试验
招募中
不适用
Study of pemetrexed in previously-treated patients with advanced squamous cell lung carcinoma having low level of TSKCT0003518CC Hospital32
尚未招募
不适用
Pemetrexed for advanced thymic epithelial tumorsNeoplasmsKCT0004180Asan Medical Center38
招募中
2 期
Phase II Study of Pemetrexed in Combination with Carboplatin Followed by Pemetrexed Maintenance Therapy for Elderly Advanced Non-squamous and Non-small Cell Lung Cancer.on-squamous non-small-cell lung cancerJPRN-UMIN000006139Tochigi Thoracic Oncology Research Organization50
已完成
2 期
A Phase 2 Study of Pemetrexed in Patients with Previously Treated Non-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000002467Kobe Lung Cancer Study Group45
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEstudio en fase II de pemetrexed en combinación con cisplatino y cetuximab en el carcinoma de células escamosas de cabeza y cuello recurrente o metastásicoRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCarcinoma de células escamosas de cabeza y cuello recurrente o metastásicoMedDRA version: 12.0Level: LLTClassification code 10063569Term: Metastatic squamous cell carcinomaEUCTR2009-011611-21-ESEli Lilly and Company Ltd.65